Milez – *Adopted*
He is a 5 year neutered male. He found his way into rescue when his family could no longer care for him medically. He has dry eye in one eye that does require daily drops for the rest of his life. Milez tends to have ear infections that do need to be treated when they occur. He, like many Bulldogs, can have skin issues that need to be dealt with when and if they arise. A good quality diet can be very helpful.
Milez is an adorable teddy bear and just wants to be right by your side. He is a great companion dog. He has been an inside dog and is good with kids.
Milez gets along with other dogs according to his Foster Mom. Also, while Milez was in Rescue we determined he had a Urinary Tract Infection (UTI) After, further testing we found out Milez has Bladder Cancer. At first, we were all pretty devastated , thinking we were going to have to euthanize Milez right then and there. Dr. Wolf said dogs on an inexpensive medication treatment have had great success in surviving for a year or more with a good quality of life. So, we decided to give Milez the opportunity of spending the rest of his life with a family willing to open up their heart and home to a loveaBULL Boy, who still has a lot of life and love to give to somebody.
What is the prognosis for dogs with TCC (Bladder Cancer) ?
Early studies reported survival in dogs with TCC as “0 days”. At that time, it was thought there was “no hope” and many dogs were euthanized at the time of diagnosis. It is not known how long dogs with TCC that are not treated will live. Survival is affected by the growth rate of the tumor, the exact location of the tumor within the bladder, and whether the tumor has spread to other organs or not. The median (“average”) survival in 55 dogs treated with surgery alone (before drugs that could help were identified) was 109 days. The median survival in dogs treated with early chemotherapy alone (cisplatin or carboplatin) at Purdue University was 130 days. Median survival with piroxicam treatment in 62 dogs with TCC was 195 days. As mentioned above, approximately 35% of dogs receiving mitoxantrone and piroxicam have remission, and the average survival is around 250-300 days. The survival times in all of these studies, however, varied tremendously from dog to dog. Some dogs died after only a few days, while others lived more than two years. As mentioned above, dogs who live the longest are those that receive more than one treatment protocol (one after the other switching therapies when the cancer begins to grow) during the course of the cancer. Factors that have been identified in our studies that negatively affect survival time include more extensive tumor within the bladder, spread of tumor beyond the bladder, and involvement of the tumor in the prostate gland. Regarding metastasis of TCC in dogs, approximately 20% of dogs with TCC have detectable metastasis at diagnosis, and 50-60% have metastasis at death. Although progress has been made, and TCC is considered a very “treatable” disease, there is still much to be learned. We are not satisfied with the “efficacy” of current therapy, especially long term. Therefore, we are continuing to study TCC to determine better ways to prevent, manage, and treat this cancer.